期刊文献+

新型降血糖药物西他格利汀的研究进展 被引量:7

下载PDF
导出
摘要 目的简述二肽基肽酶Ⅳ(DPP-4)抑制剂西他格利汀的研究进展。方法以近年来的研究文献为基础,对西他格利汀的药理作用、药动学、临床研究和药物不良反应等进行综述。结果与结论西他格利汀是一种口服有效的特异性DPP- 4抑制剂,能增强GLP-1活性和降低Ⅱ型糖尿病人的血糖。无论是单用还是与其他抗糖尿病药物合用,均能明显降低具有临床意义的HbAlC水平。从总体上来说,该药具有良好的耐受性,没有体重增加等不良反应,低血糖和胃肠道等不良反应发生率也较低。
出处 《中国药学杂志》 CAS CSCD 北大核心 2008年第13期965-967,共3页 Chinese Pharmaceutical Journal
  • 相关文献

参考文献23

  • 1International diabetes federation. Did you know[ EB/OL]. [2006- 09-23]. http://www, idf. org/home/index, cfm? unode =3B96906B - C026 - 2FD3 - 87B73 F80BC22682A. 被引量:1
  • 2KIM D, WANG L, BECONI M, et al. (2R)4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro [ 1,2, 4 ] triazolo [ 4, 3-a ] pyrazin-7 (8H) -yl ] -1 -( 2,4,5-trifluorophenyl ) butan-2-amine : A potent, orally active dipeptidyl peptidase Ⅳ inhibitor for the treatment of type 2 diabetes[J]. J Med Chem, 2005,48( 1 ) :141-151. 被引量:1
  • 3NAUCK M A, MEIER J J. Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes [ J ]. Regul Pept, 2005, 124(Suppl) :135-148. 被引量:1
  • 4DRUCKER D J. Enhancing incretin action for the treatment of type 2 diabetes [ J ]. Diabetes Care, 2003,26 ( 10 ) :2929-2940. 被引量:1
  • 5NAUCK M A, NIEDEREICHHOLZ U, ETrLER R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans [ J ]. Am J Physiol (Endocrinol Metab), 1997,273 (5) :981-988. 被引量:1
  • 6PERFETTI R, HUI H. The role of GLP-1 in the life and death of pancreatic beta cells [ J ]. Horm Metab Res, 2004,36 ( 11-12 ) : 804-810. 被引量:1
  • 7TRUMPER A, TRUMPER K, TRUSHEIM H, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling [ J ]. Mol Endocrinol, 2001,15(9) :1559-1570. 被引量:1
  • 8MENTLEIN R. Dipeptidyl-peptidase Ⅳ (CD26) -role in the inactivation of regulatory peptides [ J ]. Regul Pept, 1999,85 ( 1 ):9- 24. 被引量:1
  • 9MARGUET D, BAGGIO L, KOBAYASHI T, et al. Enhanced secretion and improved glucose tolerance in mice lacking CD26 [J]. Proe Natl Acad Sci USA, 2000,97(12) :6874-6879. 被引量:1
  • 10NAGAKURA T, YASUDA N, YAMAZAKI K, et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase Ⅳ deficient Fischer rats[J]. Biochem Biophys Res Commun, 2001,284 (2) :501-506. 被引量:1

同被引文献193

  • 1中国成人2型糖尿病HbA_(1c)控制目标的专家共识[J].中国医学前沿杂志(电子版),2011,3(4):73-77. 被引量:29
  • 2郝元涛,孙希凤,方积乾,吴少敏,朱淑明.量表条目筛选的统计学方法研究[J].中国卫生统计,2004,21(4):209-211. 被引量:175
  • 3宋秀霞 ,纪立农 .国际糖尿病联盟代谢综合征全球共识定义[J].中华糖尿病杂志(1006-6187),2005,13(3):178-180. 被引量:612
  • 4杨廷侠,刘成亮.二甲双胍不同剂型治疗2型糖尿病的药物经济学评价[J].华北煤炭医学院学报,2006,8(4):533-534. 被引量:6
  • 5黄建权,傅得兴,胡欣,张君仁.抗糖尿病药物维达列汀[J].中国新药杂志,2007,16(6):486-488. 被引量:11
  • 6Thornberry NA, Weber AE, Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[J]. Curr Top Med Chem, 2007, 7(6): 557-568. 被引量:1
  • 7Havale SH, Pal M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes[J]. Bioorg Med Chem, 2009, 17(5): 1783-1802. 被引量:1
  • 8Edmondson SD, Mastracchio A, Duffy JL, et al. Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors[J]. Bioorg Med Chem Lett, 2005, 15(12): 3048-3052. 被引量:1
  • 9Pei Z, Li X, yon Geldern TW, et al. Discovery of ((4R,sS)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex- 1 -enyl) -(3-(trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo [4,3-a]pyrazin-7(SH)-yl)methanone (ABT-341), a highly potent, selective, orallyefficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[J]. J Med Chem, 2006, 49(22): 6439-6442. 被引量:1
  • 10Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4- [3-(trifluoromethyl)-5,6-dihydro [ 1,2,4]triazolo[4,3-a]pyrazin-Y(SH)-yl]- 1 -(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[J]. J Med Chem, 2005, 48(1): 141-151. 被引量:1

引证文献7

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部